DOVER, Del.–(BUSINESS WIRE)–Inteliquet, a leading provider of intelligent technology, insights, and services for optimizing clinical trials and research, announced today that it has hired industry veteran Peter B. Malamis as Senior Vice President, Life Sciences, effective immediately. He leads the group responsible for the sale and delivery of solutions to pharmaceutical and biotechnology companies, contract research organizations (CROs), and other biopharma related groups using patient data. He also oversees the expansion of the company’s life sciences offerings.

With complex clinical trials increasingly the norm, especially in oncology, life science companies and CROs face intensified pressure to implement trials faster, as well as with more precision in their design and recruitment. Inteliquet’s offering enables better trial designs and faster patient identification and enrollment.

“As demand for Inteliquet’s unique digital, data-driven clinical research solutions steadily increases, we’re excited to have Peter lead our efforts in this area,” said Marie E. Lamont, Inteliquet’s Interim President and Chief Operating Officer. “The current pandemic intensified the attention on one of the most intractable problems of our industry: the need for rapid, real-time access to robust patient data that fuels clinical research. Even before now, the scope of required patient data for immunotherapeutic research and personalized drug development challenged trial strategy, design, and recruitment. Peter is a perfect fit with Inteliquet’s heritage and growth strategy. Along with his ‘clinical digital mindset,’ his extensive CRO background and clear understanding of our markets and healthcare partners allow us to move quickly in an environment that changes daily.”

Before Inteliquet, Peter was co-founder and CEO of CRO Analytics, a provider of a cloud-based clinical trial performance system platform. Previously, he was Vice President and General Manager at the MAPI Group, where he helped lead an acquisition that created the largest global CRO devoted to post-marketing research. He was also President of US Operations for the CRO Premier Research and held senior roles at SCIREX (US-focused CRO acquired by Premier), Galt Associates (drug safety and software services), MEDTAP International (health economics and outcomes), and PAREXEL International.

“Clients are seeing that no system can deidentify and normalize electronic medical record data as quickly and accurately as Inteliquet’s solutions,” said Malamis. “More importantly, we can provide the technology they need, but technology alone rarely wins the day. It also takes people who understand the intersection of the technology with the client need to be successful. Inteliquet has a strong, proven foundation of smart, experienced people who never forget their work helps to improve and save lives. We are driven to help our clients and partners overcome challenges as efficiently as possible, so they can bring new therapies to patients as quickly as possible.”

About Inteliquet

Inteliquet is a leading provider of technology, insights and expertise for clinical research, patient treatment, and translational medicine strategies. Our proprietary platform securely, accurately, and quickly aggregates and analyzes healthcare data, helping to ensure clinical trials are designed more effectively, patients are matched to trials more rapidly and patient-care decisions are made using real-world evidence. Our team is passionate about ensuring every patient — regardless of race, geography, age, sex, economic status, or stage of disease — has access to promising therapies as soon as they become available to help improve the care they receive. Find out more at; follow us on  LinkedIn and Facebook.


An IQVIA Business

Contact Us

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry dedicated to delivering actionable insights. Learn more at

© Copyright 2021 Inteliquet, an IQVIA business.